JP Morgan Private Capital closes first biotech VC fund above $500m

Private Equity Wire

JP Morgan Private Capital, JP Morgan’s venture capital and growth equity investment team has held the final close of 270 Life Sciences Private Capital Fund I, above its $500m target. 

LSPCF received commitments from institutional allocators, strategic corporate partners, family offices and HNWIs across North America, Europe, the Middle East and Asia, as well as JPMorgan Chase & Co. The fund close was led by CIO Stephen Squinto and Managing Partner Gaurav Gupta. 

LSPCF invests in private biotechnology companies spanning cardiometabolic disease, oncology, immunology and genetic medicines. 

The full article is available here. This article was published at Private Equity Wire.